David Malcom Rodman Sells 2,170 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 2,170 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $27.09, for a total transaction of $58,785.30. Following the transaction, the insider directly owned 51,384 shares of the company’s stock, valued at approximately $1,391,992.56. This represents a 4.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Malcom Rodman also recently made the following trade(s):

• On Thursday, July 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $30.30, for a total transaction of $65,781.30.
• On Wednesday, June 17th, David Malcom Rodman sold 4,584 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $25.00, for a total transaction of $114,600.00.
• On Monday, June 15th, David Malcom Rodman sold 9,890 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $23.81, for a total transaction of $235,480.90.
• On Friday, June 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $23.93, for a total transaction of $151,931.57.
• On Wednesday, June 10th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $25.00, for a total value of $54,250.00.
• On Monday, May 18th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.55, for a total value of $11,488.35.

Mineralys Therapeutics Stock Performance

NASDAQ:MLYS opened at $26.09 on Friday. Mineralys Therapeutics, Inc. has a 52-week low of $13.40 and a 52-week high of $47.65. The stock has a fifty day moving average of $26.44 and a 200 day moving average of $27.55. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -6.15 and a beta of 0.68.

Mineralys Therapeutics (NASDAQ:MLYS) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($2.30). Equities analysts forecast that Mineralys Therapeutics, Inc. will post -2.3 earnings per share for the current fiscal year.

Key Headlines Impacting Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: Potential FDA decision remains on schedule: Mineralys reiterated a December 22, 2026 PDUFA date for lorundrostat, its investigational treatment for hypertension. The company also said commercial launch preparations are progressing, supporting the possibility of a near-term regulatory catalyst. Mineralys launch readiness and cash runway
• Positive Sentiment: Cash runway reduces near-term financing risk: Management indicated that its cash position could fund operations into 2028. The company also highlighted steps intended to improve lorundrostat’s economics, including repurchasing the Tanabe royalty obligation. Cash runway and launch readiness
• Positive Sentiment: New chief medical officer appointed: Dr. Terry Ferguson will lead medical strategy and late-stage clinical activities ahead of a potential lorundrostat launch. The board granted him inducement awards covering 135,000 stock options and 102,400 restricted stock units. Mineralys inducement award announcement
• Neutral Sentiment: Analyst remains bullish but trimmed estimates: HC Wainwright maintained its Buy rating while lowering its FY2030 EPS forecast to $3.41 from $3.73, signaling modestly reduced long-term expectations.
• Negative Sentiment: Large quarterly earnings miss: Mineralys reported a second-quarter loss of $2.85 per share, substantially wider than the $0.55 consensus loss. The result may increase investor concerns about spending and execution ahead of commercialization. Mineralys second-quarter earnings call transcript
• Negative Sentiment: Insider selling adds a cautious signal: David Malcom Rodman sold 2,170 shares for approximately $58,785 under a pre-arranged Rule 10b5-1 plan. While scheduled sales are not necessarily discretionary, the transaction reduced his direct holdings by 4.05%. Mineralys insider sale

Analyst Upgrades and Downgrades

A number of research firms have commented on MLYS. HC Wainwright reissued a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. TD Cowen initiated coverage on shares of Mineralys Therapeutics in a research report on Monday, April 27th. They set a “buy” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. Wall Street Zen lowered shares of Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Jefferies Financial Group reissued a “hold” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Mineralys Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $49.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of MLYS. Navalign LLC bought a new stake in shares of Mineralys Therapeutics in the 4th quarter worth approximately $33,000. KBC Group NV bought a new position in shares of Mineralys Therapeutics during the 1st quarter valued at $33,000. Royal Bank of Canada raised its position in Mineralys Therapeutics by 262.3% in the 4th quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock worth $56,000 after purchasing an additional 1,107 shares during the period. FNY Investment Advisers LLC raised its position in Mineralys Therapeutics by 400.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 2,500 shares of the company’s stock worth $67,000 after purchasing an additional 2,000 shares during the period. Finally, Caitong International Asset Management Co. Ltd raised its position in Mineralys Therapeutics by 1,845.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,101 shares of the company’s stock worth $76,000 after purchasing an additional 1,993 shares during the period. 84.46% of the stock is currently owned by institutional investors.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.